Liver failure

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Donnerstag, Mai 9, 2024
Inflammation, News, Suite, Liver failure, MarketWatch, RAPT, Ethics, Therapy, Security (finance)

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT ) for violations of the securities laws.

Key Points: 
  • LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Phase 10, Research, Consultant, Patient, Liver failure, Inflammation, Clinical trial, Atopic dermatitis, Therapy, Asthma, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.
  • Concurrently, we are continuing our investigation and analysis of the serious adverse event that triggered the clinical hold.”
    Financial Results for the First Quarter March 31, 2024
    First Quarter Ended March 31, 2024
    Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023.
  • Research and development expenses for the first quarter of 2024 were $24.8 million, compared to $25.6 million for the same period in 2023.
  • General and administrative expenses for the first quarter of 2024 were $7.7 million, compared to $6.0 million for the same period in 2023.

Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease

Retrieved on: 
Montag, April 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, USD, Cirrhosis, Genomics, CLD, Liver disease, Boehringer Ingelheim, Chronic liver disease, Machine learning, The Gentle Touch, RNA, Partnership, Liver regeneration, Senior, Patient, Liver failure, DSM-IV codes, Disease, CRM, Boehringer, MASH, Outsourcing, Copper

Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Key Points: 
  • Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
  • Boehringer Ingelheim aims to develop new treatments modulating innovative regenerative targets with the potential to enhance the liver’s self-repair capabilities to prevent or reverse disease progression.
  • It builds on Ochre Bio’s leading capabilities to leverage human data and disease models to accelerate the discovery and validation of novel liver disease targets.
  • “Ochre Bio brings to the table unique and exciting capabilities in liver disease research.

First National Study to Assess the Prevalence of NAFLD to be Conducted by Federal Government

Retrieved on: 
Donnerstag, April 25, 2024
Congress, Fatty liver disease, ALF, Language, NAFLD, Liver disease, Risk, Hispanic, AHRQ, Overweight, Diabetes, FAST, Partnership, Agency, Research, American Liver Foundation, Disease, Obesity, Labour, NASH, Patient, Liver failure, Society, Metabolic syndrome, American Society of Transplantation, Liver transplantation, Prevalence, Dietary supplement

NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.

Key Points: 
  • NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
  • New national study to assess prevalence of NAFLD to be conducted, ALF grateful to Congress and advocates.
  • "We are so grateful to Senator Bill Cassidy (R-LA) for his leadership in championing this effort on Capitol Hill.
  • In an online liver health quiz to assess risk factors, 93% of respondents received a positive result for being at risk for NAFLD.

TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024

Retrieved on: 
Dienstag, April 16, 2024
Heart, Patient, Liver failure

ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024.

Key Points: 
  • ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call.
  • A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Mittwoch, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Montag, April 8, 2024
Patient, Liver failure, Compensated emancipation, Employment, Heart

The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

Key Points: 
  • The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
  • TransMedics granted non-qualified stock options to purchase 9,722 shares of TransMedics' common stock and 6,322 restricted stock units in the aggregate.
  • The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
  • The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Donnerstag, März 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Retrieved on: 
Montag, März 18, 2024
Infectious Diseases, Hospitals, Public Policy, Government, Philanthropy, Managed Care, Health, State, Local, General Health, Foundation, Pregnancy, Liver failure, HBI, Organization, University, Hepatitis B, Disease, CDA, Cirrhosis, Patient, Public, HBV, Woman, Viral hepatitis, Medicaid, Liver cancer, Refugee, HCV, Pharmaceutical industry

“CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.

Key Points: 
  • “CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.
  • “Loss of diagnosed but untreated patients is a major barrier for countries trying to achieve the viral hepatitis elimination targets.
  • The submission window for the second round of proposals opened in February 2024 for programs with a duration of no more than 18 months.
  • For more information, please visit https://cdafound.org/relink or contact CDA Foundation at [email protected] .

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Dienstag, März 19, 2024
Patient, Liver failure, Compensated emancipation, Employment, Heart

The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

Key Points: 
  • The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
  • TransMedics granted non-qualified stock options to purchase 9,418 shares of TransMedics' common stock and 6,149 restricted stock units in the aggregate.
  • The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
  • The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.